V. C. D. de Lima

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC

P. de Marchi, R. Cavagna, L. D. da Silva, 2023, Translational oncology.

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study

R. Rosell, A. Cardona, L. Raez, 2023, Targeted Oncology.

Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors

A. Cardona, O. Arrieta, U. Malapelle, 2022, ESMO open.

NDRG4 promoter hypermethylation is a mechanistic biomarker associated with metastatic progression in breast cancer patients

A. Camargo, R. Moura, H. Brentani, 2019, npj Breast Cancer.